iTRAQ technology combined 2DLC-MS/MS differentially expressed proteins in prostate cancer screening

Chuan-yu SUN,Xiao-jun ZHAO,Ke XU,Yuan-cheng GOU,Wei-hong DING,Qing-feng HU,Guo-wei XIA,Qiang DING
DOI: https://doi.org/10.3969/cma.j.issn.1674-0785.2013.13.035
2013-01-01
Abstract:Objective To screen differentially expressed proteins of prostate cancer by the proteomics analysis using isobaric tags for relative and absolute quantification ( iTRAQ ) combined with two-dimensional liquid chromatography-tandem mass spectrometry (2DLC-MS/MS).Methods The patients undergoing prostate biopsies were classified in 3 groups:benign prostate hyperplasia(n=20),prostate cancer(n=20)and prostatic intraepithelial neoplasm(n=10).After quantification and enzymolysis of the protein extract from the specimens of the 3 groups,the iTRAQ regents 114,116 and 117 were used to label the peptides of the 3 groups respectively .Then,the mixture of the peptides was analyzed by 2DLC-MS/MS.The MS/MS data were searched against the International Swissprot (090210,Human)using the Protein Pilot software(version 3.0)for peptide identification and quantification .The fold change cutoff ratio>1.50 or <0.66 was selected to designate proteins of differential expression ( P<0.05 ) .Several differentially expressed proteins such as Tumor protein D 52(TPD52),Prohibitin-2,Elongation factor Tu(EF-Tu)and Decorin were verified by Western-blot assay .Results A total of 760 proteins were identified from the International Swissprot ( 090210 , Human ) .Based on the condition of screening differentially expressed proteins , comparing with BPH,20 proteins were significantly up-regulated ( >1.5-fold ) and 26 were significantly down-regulated in PCa (<0.66-fold).TPD52,Prohibitin-2,EF-Tu were significantly up-regulated(4.25 fold,4.57 fold and 3.02 fold, respectively)and Decorin was down-regulated(0.43 fold)in PCa.The results of Western-blot assay were consistent with the proteomic changes of these 4 proteins.Conclusion The differentially expressed proteins of PCa identified by proteomic analysis using iTRAQ are reliable .The iTRAQ technology provides a good platform to identify more significant biomarkers of PCa .
What problem does this paper attempt to address?